Rani Therapeutics enters $150M ATM equity offering agreement with Cantor and H.C. Wainwright

Rani Therapeutics Holdings, Inc.

Up to $150M of Class A common stock may be sold at market prices on Nasdaq through agents Cantor Fitzgerald and H.C. Wainwright.
Agent compensation set at up to 3.0% of gross sales price per share sold.
Offering under effective shelf registration (Form S-3, effective Aug 10, 2022); prospectus supplement filed Aug 24, 2022.
Rani not obligated to sell any shares; agreement may be terminated by either party with 10 days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.